Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography
- 24 January 2000
- journal article
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 738 (1) , 155-163
- https://doi.org/10.1016/s0378-4347(99)00513-7
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.British Journal of Cancer, 1998
- Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11Cancer Letters, 1998
- Sensitivity to camptothecin of human breast carcinoma and normal endothelial cellsCancer Chemotherapy and Pharmacology, 1997
- Topoisomerase I Inhibition by the Camptothecin Analog G1147211C.Annals of the New York Academy of Sciences, 1996
- Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationBritish Journal of Cancer, 1996
- Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase IJournal of Medicinal Chemistry, 1995
- Antitumor effect of liposome-incorporated camptothecin in human malignant xenograftsAnti-Cancer Drugs, 1995
- Stabilization of Topotecan in Low pH Liposomes Composed of DistearoylphosphatidylcholineJournal of Pharmaceutical Sciences, 1994
- Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activityJournal of Medicinal Chemistry, 1989
- Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2Journal of the American Chemical Society, 1966